WHY IT MATTERS: Patients exploring THC-free options for mood support should know that CBC products are now commercially available, but the clinical evidence base is still largely preclinical and has not yet established clear dosing guidelines or confirmed efficacy in human trials. CLINICAL OVERVIEW: Cannabichromene (CBC) is a non-intoxicating phytocannabinoid that interacts with the endocannabinoid system through mechanisms distinct from CBD and THC, including potential influence on anandamide availability rather than direct binding at CB1 or CB2 receptors. Early preclinical research points toward possible mood-related and anti-inflammatory effects, though human clinical trial data remains limited.